Geode Capital Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-45,363
| Closed | -$16.8K | – | 4816 |
|
|
2023
Q3 | $16.8K | Buy |
+45,363
| New | +$25.9K | ﹤0.01% | 4655 |
|
|
2022
Q4 | – | Sell |
-1,639
| Closed | -$16K | – | 5082 |
|
|
2022
Q3 | $16K | Sell |
1,639
-2
| -0.1% | -$47 | ﹤0.01% | 4943 |
|
|
2022
Q2 | $55K | Buy |
1,641
+151
| +10% | +$7.06K | ﹤0.01% | 4755 |
|
|
2022
Q1 | $105K | Buy |
1,490
+1,006
| +208% | +$186K | ﹤0.01% | 4646 |
|
|
2021
Q4 | $148K | Sell |
484
-3
| -0.6% | -$1.88K | ﹤0.01% | 4603 |
|
|
2021
Q3 | $383K | Buy |
487
+105
| +27% | +$91.3K | ﹤0.01% | 4156 |
|
|
2021
Q2 | $406K | Buy |
382
+89
| +30% | +$116K | ﹤0.01% | 4036 |
|
|
2021
Q1 | $527K | Buy |
293
+241
| +463% | +$482K | ﹤0.01% | 3787 |
|
|
2020
Q4 | $73K | Buy |
52
+8
| +18% | +$16.4K | ﹤0.01% | 4111 |
|
|
2020
Q3 | $170K | Hold |
44
| – | – | ﹤0.01% | 3767 |
|
|
2020
Q2 | $256K | Sell |
44
-37
| -46% | -$178K | ﹤0.01% | 3591 |
|
|
2020
Q1 | $279K | Sell |
81
-7
| -8% | -$66.1K | ﹤0.01% | 3450 |
|
|
2019
Q4 | $850K | Buy |
+88
| New | +$751K | ﹤0.01% | 3326 |
|
Geode Capital Management's BXRX Position: Q4 2023 in Review
Geode Capital Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 45,363 shares — an estimated $16.8K sold.
Geode Capital Management first reported a position in BXRX in Q4 2019 and held it in 13 quarters. The position peaked at $850K in Q4 2019. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.
- Geode Capital Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Geode Capital Management sold 45,363 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $16.8K.
- Geode Capital Management first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 13 quarters.
- Geode Capital Management's Baudax Bio, Inc. Common Stock position peaked at $850K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.
Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.